AMRI has announced positive results from a Phase I clinical study of its MCH1 receptor antagonist, ALB-127158(a), used to treat obesity. The placebo-controlled study evaluated the safety, tolerability and efficacy of ALB-127158(a) in male volunteers. The drug was found to be
AMRI has announced positive results from a Phase I clinical study of its MCH1 receptor antagonist, ALB-127158(a), used to treat obesity.
The placebo-controlled study evaluated the safety, tolerability and efficacy of ALB-127158(a) in male volunteers.
The drug was found to be well tolerated in both the single ascending-dose arm and the 14-day ascending-dose arm.
The common adverse event reported in both arms was loss of appetite.
